The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Sarclisa Escena
isatuximab-irfc · ISATUXIMAB 140 mg/mL · Injection, Solution · Subcutaneous · Sanofi-Aventis U.S. LLC
NDC 00024-0674-01 · 1 VIAL in 1 CARTON / 10 mL in 1 VIAL · BLA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 3 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $9,979.92 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- BLA761445
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of isatuximab-irfc (Injection, Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | ISATUXIMAB 140 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Sarclisa Escena — NDC 00024-0674-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00024067401.
Free to cite with attribution — see how the data is put together.